3-octanone

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

1.	Cordobés, Shandra: 1 article (04/2011)
2.	Espeso, Eduardo A: 1 article (04/2011)
3.	Garzia, Aitor: 1 article (04/2011)
4.	Herrero-Garcia, Erika: 1 article (04/2011)
5.	Ugalde, Unai: 1 article (04/2011)
6.	Elfman, L: 1 article (04/2007)
7.	Kim, J L: 1 article (04/2007)
8.	Mi, Y: 1 article (04/2007)
9.	Norbäck, D: 1 article (04/2007)
10.	Smedje, G: 1 article (04/2007)

1.	Acute Coronary Syndrome 01/01/2023 - "Random forest identified methylglutarylcarnitine and lysoPC (18:0) as the metabolic markers (mean decrease gini >1.0) for non-significant CVDs (nos-CVDs) versus normal coronary artery (NCA), 1,3-Octadiene and 3-Octanone for acute coronary syndrome (ACS) versus nos-CVDs, and lysoPC (18:0) for acute coronary syndrome versus normal coronary artery. "
2.	Starvation 04/01/2011 - "The action of 3-octanone required functional forms of developmental activators fluG, flbB-D and brlA, and was not additive to the conidiogenic effect of stress stimuli such as osmotic stress or carbon starvation. "
3.	Paralysis (Palsy) 01/18/2023 - "Treatment of Caenorhabditis elegans with 3-octanone recapitulates the rapid paralysis, calcium influx, and neuronal cell death arising from fungal contact. "
4.	Dyspnea (Shortness of Breath) 04/01/2007 - "Moreover, there were positive associations between nocturnal breathlessness and 3-methylfuran (P < 0.01), 3-methyl-1-butanol (P < 0.05), dimethyldisulfide (P < 0.01), 2-heptanone (P < 0.01), 1-octen-3-ol (P < 0.05), 3-octanone (P < 0.05), TMPD-MIB (P < 0.05), and TMPD-DIB (P < 0.01). "